Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824174 | 0.94 | PARP1 (0.60) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL25159913 | 0.85 | PARP1 (0.52) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL15484864 | 0.85 | PARP1 (0.52) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL1363884 | 0.84 | PARP1 (0.50) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL12607365 | 0.84 | PARP1 (0.50) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL31222695 | 0.84 | PARP1 (0.50) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL1363329 | 0.84 | PARP1 (0.50) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL5223135 | 0.84 | PARP1 (0.50) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL553127 | 0.80 | PARP1 (0.47) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL25432683 | 0.79 | PARP1 (0.55) | PARP1TSHRHTTAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117110458-A | Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry | 浙江工业大学 | 2023-11-24 | — | — | CN | claimed |
| CN-105363394-B | A kind of preparation and application of the magnetic fluorescence molecular engram nanoparticle for detecting nitrobenzene | 济南大学 | 2017-11-07 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | US | claimed |
| WO-2004075864-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| CN-117110458-B | Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry | 浙江工业大学 | 2025-10-31 | — | — | CN | disclosed |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
| CN-117110458-A | Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry | 浙江工业大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-117110458-A | Method for detecting halogenated benzamide by solid phase extraction-liquid chromatography tandem mass spectrometry | 浙江工业大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-105363394-B | A kind of preparation and application of the magnetic fluorescence molecular engram nanoparticle for detecting nitrobenzene | 济南大学 | 2017-11-07 | — | — | CN | disclosed |
| US-8778219-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2013-12-19 | — | — | US | disclosed |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH HEALTH US, LLC | 2008-02-07 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008005686-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004075864-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-4147725-A | Process for preparing aniline compounds from amides with rhodium | THE DOW CHEMICAL COMPANY (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | POU2F1, POU2F2, POF1B | PARP1 4538/4885TSHR 4283/4885HTT 3924/4885 |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | PTGIR, GCGR, NR3C1 | PARP1 3365/4885TSHR 375/4885HTT 3695/4885 |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | NR3C1, GCGR, GPBAR1 | PARP1 3952/4885TSHR 78/4885HTT 4296/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | PARP1 3014/4885TSHR 2744/4885HTT 3953/4885 |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | PARP1 908/4885TSHR 4794/4885HTT 438/4885 |
| US-20040224992-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | PARP1 3405/4885TSHR 586/4885HTT 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.